Osteoporosis

Decision aids for osteoporosis currently lack quality standards and do not meet patient needs, results of a mixed-methods study showed.

Women with primary ovarian insufficiency prescribed combined oral contraceptives experienced an increase in bone density at the lumbar spine and total femur compared with similar women prescribed other hormone formulations or no treatment.

Evenity, a monoclonal antibody that inhibits sclerostin used to treat osteoporosis, may increase patients’ risk for adverse cardiovascular events, according to research published in Science Translational Medicine.

Long-term use of unfractionated heparin may be associated with the loss of lumbar spine bone mineral density in patients undergoing maintenance hemodialysis treatment, according to a published study.

Women with postmenopausal osteoporosis who received the monoclonal antibody romosozumab were less likely to sustain a vertebral fracture during 12 months of treatment compared with women who received placebo or alendronate, study data show.

A cohort of Canadian adults prescribed statins, and hydrophilic statins, in particular, had higher levels of insulin resistance compared with non-statin users, according to findings published in the Journal of the Endocrine Society.

Older adults prescribed nitrogen-containing bisphosphonate therapy after a hip fracture were less likely to develop pneumonia or die from the infection compared with similar adults who received no osteoporosis therapy, researchers report.

Medtronic plc announced the U.S. launch of its Kyphon Assist Directional Cannula for use with its balloon kyphoplasty products to treat vertebral compression fractures due to osteoporosis, cancer or benign lesions.

A cohort of Asian adults were 3.4 times more likely to experience an atypical femur fracture compared with non-Asian adults, although the incidence was still low, according to findings published in Bone.

A baseline fracture risk should guide the selection of initial osteoporosis therapy for postmenopausal women, and treatment should be continued for as long as the expected benefits outweigh the potential risks, according to an updated guideline from the American Association of Clinical Endocrinologists and the American College of Endocrinology.